Clin Colon Rectal Surg 2004; 17(2): 89-98
DOI: 10.1055/s-2004-828655
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

High-Output Fistula

Naila Arebi1 , Alastair Forbes1
  • 1Department of Medicine, St. Mark's Hospital, Harrow, Middlesex, United Kingdom
Further Information

Publication History

Publication Date:
27 May 2004 (online)

Despite improvements in healthcare delivery, mortality rates for high-output fistulae remain unchanged. The pathophysiology and causes of fistulae are reviewed in this article. An overview of the diagnostic procedures to delineate fistulae and underlying bowel disease together with their complications is included. Management of high-output fistulae consists of assessment and stabilization of patients, followed by conservative management by a multidisciplinary team until spontaneous or surgical closure of fistulae.

REFERENCES

  • 1 Edmunds Jr L H, Williams G M, Welch C E. External fistulas arising from the gastro-intestinal tract.  Ann Surg. 1960;  152 445-471
  • 2 Rocchio M A, Cha C J, Haas K F, Randall H T. Use of chemically defined diets in the management of patients with high output gastrointestinal cutaneous fistulas.  Am J Surg. 1974;  127 148-156
  • 3 Deitel M. Nutritional management of external gastrointestinal fistulas.  Can J Surg. 1976;  19 505-509
  • 4 Sitges-Serra A, Jaurrieta E, Sitges-Creus A. Management of postoperative enterocutaneous fistulas: the roles of parenteral nutrition and surgery.  Br J Surg. 1982;  69 147-150
  • 5 McIntyre P B, Ritchie J K, Hawley P R. Management of enterocutaneous fistulas: a review of 132 cases.  Br J Surg. 1984;  71 293-296
  • 6 Athanassiades S, Notis P, Tountas C. Fistulas of the gastrointestinal tract. Experience with eighty-one cases.  Am J Surg. 1975;  130 26-28
  • 7 Chamberlain R S, Kaufman H L, Danforth D N. Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment.  Am Surg. 1998;  64 1204-1211
  • 8 Feldman M, Goldschmiedt M. Gastric HCO3-secretion: relationship with Na+ secretion and effect of acetazolamide in humans.  Am J Physiol. 1991;  261(2 Pt 1) G320-G326
  • 9 Read N W, Cooper K, Fordtran J S. Effect of modified sham feeding on jejunal transport and pancreatic and biliary secretion in man.  Am J Physiol. 1978;  234 E417-E420
  • 10 Kidd M, Modlin I M, Tang L H. Gastrin and the enterochromaffin-like cell: an acid update.  Dig Surg. 1998;  15 209-217
  • 11 Drucker D J, Erlich P, Asa S L, Brubaker P L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2.  Proc Natl Acad Sci USA. 1996;  93 7911-7916
  • 12 Jeppesen P B, Hartmann B, Thulesen J et al.. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.  Gastroenterology. 2001;  120 806-815
  • 13 Alexander E S, Weinberg S, Clark R A, Belkin R D. Fistulas and sinus tracts: radiographic evaluation, management, and outcome.  Gastrointest Radiol. 1982;  7 135-140
  • 14 Cresci G A, Martindale R G. Metabolic and nutritional management of a patient with multiple enterocutaneous fistulas.  Nutrition. 1997;  13 446-448
  • 15 Gasche C, Moser G, Turetschek K, Schober E, Moeschl P, Oberhuber G. Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease.  Gut. 1999;  44 112-117
  • 16 Maconi G, Parente F, Porro G B. Hydrogen peroxide enhanced ultrasound-fistulography in the assessment of enterocutaneous fistulas complicating Crohn's disease.  Gut. 1999;  45 874-878
  • 17 Maconi G, Sampietro G M, Parente F et al.. Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study.  Am J Gastroenterol. 2003;  98 1545-1555
  • 18 Orel S G, Rubesin S E, Jones B, Fishman E K, Bayless T M, Siegelman S S. Computed tomography vs barium studies in the acutely symptomatic patient with Crohn disease.  J Comput Assist Tomogr. 1987;  11 1009-1016
  • 19 Jobling C, Halligan S, Bartram C. The use of non-ionic water-soluble contrast agents for small bowel follow-through examination.  Eur Radiol. 1999;  9 706-710
  • 20 Potthast S, Rieber A, Von Tirpitz C, Wruk D, Adler G, Brambs H J. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison.  Eur Radiol. 2002;  12 1416-1422
  • 21 Rieber A, Nussle K, Reinshagen M, Brambs H J, Gabelmann A. MRI of the abdomen with positive oral contrast agents for the diagnosis of inflammatory small bowel disease.  Abdom Imaging. 2002;  27 394-399
  • 22 Koelbel G, Schmiedl U, Majer M C et al.. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging.  AJR Am J Roentgenol. 1989;  152 999-1003
  • 23 Bell S J, Halligan S, Windsor A C, Williams A B, Wiesel P, Kamm M A. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging.  Aliment Pharmacol Ther. 2003;  17 387-393
  • 24 Dombrowski S R, Mirtallo J M. Drug therapy and nutritional management of patients with gastrointestinal fistulas.  Clin Pharm. 1984;  3 264-272
  • 25 Bruley des Varennes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche J P. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.  Aliment Pharmacol Ther. 1994;  8 309-314
  • 26 Londong W, Londong V, Cederberg C, Steffen H. Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release.  Gastroenterology. 1983;  85 1373-1378
  • 27 Katz P O, Hatlebakk J G, Castell D O. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.  Aliment Pharmacol Ther. 2000;  14 709-714
  • 28 Deitel M. Nutritional management of external gastrointestinal fistulas.  Can J Surg. 1976;  19 505-509
  • 29 Rose D, Yarborough M F, Canizaro P C, Lowry S F. One hundred and fourteen fistulas of the gastrointestinal tract treated with total parenteral nutrition.  Surg Gynecol Obstet. 1986;  163 345-350
  • 30 Rocchio M A, Cha C J, Haas K F, Randall H T. Use of chemically defined diets in the management of patients with high output gastrointestinal cutaneous fistulas.  Am J Surg. 1974;  127 148-156
  • 31 Levy E, Frileux P, Cugnenc P H, Honiger J, Ollivier J M, Parc R. High-output external fistulae of the small bowel: management with continuous enteral nutrition.  Br J Surg. 1989;  76 676-679
  • 32 Sitges-Serra A, Jaurrieta E, Sitges-Creus A. Management of postoperative enterocutaneous fistulas: the roles of parenteral nutrition and surgery.  Br J Surg. 1982;  69 147-150
  • 33 Zera R T, Bubrick M P, Sternquist J C, Hitchcock C R. Enterocutaneous fistulas. Effects of total parenteral nutrition and surgery.  Dis Colon Rectum. 1983;  26 109-112
  • 34 McIntyre P B, Ritchie J K, Hawley P R. Management of enterocutaneous fistulas: a review of 132 cases.  Br J Surg. 1984;  71 293-296
  • 35 Wolfe B M, Keltner R M, Willman V L. Intestinal fistula output in regular, elemental, and intravenous alimentation.  Am J Surg. 1972;  124 803-806
  • 36 Chamberlain R S, Kaufman H L, Danforth D N. Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment.  Am Surg. 1998;  64 1204-1211
  • 37 Frost S. Stoma care: managing high-output fistulas.  Nurs Stand. 1991;  5 25-27
  • 38 Burch J. The nursing care of a patient with enterocutaneous faecal fistulae.  Br J Nurs. 2003;  12 736-740
  • 39 Lichtenstein G R. Treatment of fistulizing Crohn's disease.  Gastroenterology. 2000;  119 1132-1147
  • 40 Walsh J H. Gastrointestinal hormones. In: Johnson LR Physiology of the Gastrointestinal Tract. New York; Raven Press 1994: 1-128
  • 41 Pederzoli P, Bassi C, Falconi M, Albrigo R, Vantini I, Micciolo R. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin.  Surg Gynecol Obstet. 1986;  163 428-432
  • 42 Torres A J, Landa J I, Moreno-Azcoita M et al.. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial.  Arch Surg. 1992;  127 97-99
  • 43 Planas M, Porta I, Angles R, Baena J A, Serra J, Padro J B. [Somatostatin and/or total parenteral nutrition for the treatment of intestinal fistulas].  Rev Esp Enferm Dig. 1990;  78 345-347
  • 44 Torres A J, Landa J I, Moreno-Azcoita M et al.. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial.  Arch Surg. 1992;  127(1) 97-99
  • 45 Nubiola-Calonge P, Badia J M, Sancho J, Gil M J, Segura M, Sitges-Serra A. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output.  Lancet. 1987;  2 672-674
  • 46 Scott N A, Finnegan S, Irving M H. Octreotide and gastrointestinal fistulae.  Digestion. 1990;  45(Suppl 1) XS66-70 , discussion 70-71
  • 47 Sancho J J, di Costanzo J, Nubiola P et al.. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula.  Br J Surg. 1995;  82 638-641
  • 48 Hernandez-Aranda J C, Gallo-Chico B, Flores-Ramirez L A, Avalos-Huante R, Magos-Vazquez F J, Ramirez-Barba E J. [Treatment of enterocutaneous fistula with or without octreotide and parenteral nutrition].  Nutr Hosp. 1996;  11 226-229
  • 49 Hesse U, Ysebaert D, de Hemptinne B. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data.  Gut. 2001;  49(Suppl 4) iv11-iv21
  • 50 di Costanzo J, Cano N, Martin J et al.. Treatment of external gastrointestinal fistulas by a combination of total parenteral nutrition and somatostatin.  JPEN J Parenter Enteral Nutr. 1987;  11 465-470
  • 51 Ysebaert D, Van Hee R, Hubens G, Vaneerdeweg W, Eyskens E. Management of digestive fistulas.  Scand J Gastroenterol Suppl. 1994;  207 42-44
  • 52 Hild P, Dobroschke J, Henneking K, Rieck B. Treatment of enterocutaneous fistulas with somatostatin.  Lancet. 1986;  2 626
  • 53 Nubiola P, Badia J M, Martinez-Rodenas F et al.. Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995.  Ann Surg. 1989;  210 56-58
  • 54 Barnes S M, Kontny B G, Prinz R A. Somatostatin analog treatment of pancreatic fistulas.  Int J Pancreatol. 1993;  14 181-188
  • 55 O'Keefe S J, Haymond M W, Bennet W M, Oswald B, Nelson D K, Shorter R G. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies.  Gastroenterology. 1994;  107 379-388
  • 56 Berry S M, Fischer J E. Classification and pathophysiology of enterocutaneous fistulas.  Surg Clin North Am. 1996;  76 1009-1018
  • 57 Athanassiades S, Notis P, Tountas C. Fistulas of the gastrointestinal tract. Experience with eighty-one cases.  Am J Surg. 1975;  130 26-28
  • 58 Rabago L R, Ventosa N, Castro J L, Marco J, Herrera N, Gea F. Endoscopic treatment of postoperative fistulas resistant to conservative management using biological fibrin glue.  Endoscopy. 2002;  34 632-638

Alastair ForbesM.D. 

Department of Medicine, St. Mark's Hospital, Northwick Park, Watford Road, Harrow, Middlesex, HA1 3UJ, United Kingdom

Email: alastair.forbes@imperial.ac.uk